Quantifying and mapping hypoxia modification in patients with uterine cervical cancer using oxygen-enhanced MRI
Anubhav Datta1,2, Michael Dubec1,3, David Buckley3,4, Damien McHugh3, Amal Salah5, Ross Little1, Michael Berks1, Susan Cheung1, Catharine West1, Ananya Choudhury1,6, Lisa Barraclough6, Peter Hoskin1,6,7, and James P. B. O'Connor1,2,8
1Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom, 2Clinical Radiology, The Christie NHS Foundation Trust, Manchester, United Kingdom, 3Christie Medical Physics and Engineering, The Christie NHS Foundation Trust, Manchester, United Kingdom, 4School of Medicine, University of Leeds, Leeds, United Kingdom, 5Proton Beam Therapy Dept, The Christie NHS Foundation Trust, Manchester, United Kingdom, 6Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom, 7Mount Vernon Cancer Centre, Northwood, United Kingdom, 8Division of Radiotherapy and Imaging, Institute of Cancer Research, London, United Kingdom
Hypoxia is a ubiquitous negative prognostic factor in solid tumours. Oxygen-enhanced MRI can spatially map regions refractory to an oxygen challenge and, when combined with a perfusion measurement, has the potential to quantify hypoxia in vivo. We developed the technique in healthy volunteers before successfully translating into a longitudinal patient study of patients with cervical carcinoma. We present initial data to support OE-MRI quantifying and mapping hypoxia modification following therapy in this clinical dataset.
This abstract and the presentation materials are available to members only;
a login is required.